| Name | Title | Contact Details |
|---|
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering`s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering`s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.
BellBrook Labs is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genpathway, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Creative Biogene.Inc is a Shirley, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LTZ Therapeutics is an immunotherapy-focused biotech company to develop novel therapies to improve clinical outcomes in patients with cancer and other diseases with an unmet clinical need.